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Radiation-induced myelopathy after 
hypofractionated radiotherapy in women 
with spinal metastases from breast 
cancer — a case report
AbstRAct 
Hypofractionated radiotherapy, with a single dose of 8 Gy or 20 Gy given in 4–5 fractions, remains a standard treat-
ment of bone metastasis, including spine lesions. Hypofractionated radiotherapy is also used during re-irradiation. 
These schedules are associated with an increased risk of severe complications, and their differentiation from 
local tumour progression can be difficult. We describe a 55-year-old female with breast cancer, who underwent 
palliative radiotherapy with a dose of 20 Gy in four fractions to the Th6–Th10 spine levels. After four months the 
patient was referred for re-irradiation due to progression of neurological symptoms. MRI examination suggested 
local tumour progression. Due to rapid deterioration she did not receive re-irradiation, and died due to systemic 
fungal infection. Autopsy revealed extensive radiation myelopathy in previously irradiated thoracic spine, without 
the presence of cancer at the site.
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Introduction 
Breast cancer is the most frequent neoplasm diag-
nosed among women in the majority of countries, as 
well as in Poland. Bone metastases are very common in 
patients with breast cancer and are typically located in 
the axial skeleton (including spine) [1]. Palliative radio-
therapy together with surgery is the standard modality 
of local treatment of bone metastases. Beyond its anal-
gesic effect it decreases the risk of some complications, 
including neurological changes due to the presence of 
tumour mass and deformation of surrounding tissues, 
which result from bone destruction. Furthermore, in 
some cases radiotherapy can prolong survival [2]. 
Various protocols of hypofractionated irradiation 
are used during palliative radiotherapy of bone metas-
tases, most commonly with a single dose of 8 Gy or total 
dose of 20–25 Gy divided into 4–5 fractions [3]. This 
is supported by short treatment duration, and lower 
patient burden and cost. Comparable analgesic efficacy 
of single dose of 8 Gy and total dose of 20 Gy in five 
fractions was confirmed in randomised controlled trials 
[4, 5]. Hypofractionated radiotherapy is also used in 
patients with local progression of cancer in previously 
irradiated areas [6]. Administration of a fraction dose 
that is higher than a conventional one (2–2.5 Gy) is as-
sociated with higher risk of complications, particularly 
with reference to tissues of low a/b ratio, including spinal 
cord (it is assumed that the a/b ratio for spinal cord 
amounts to 1–2 Gy, depending on the part). 
Differentiation between post-irradiation changes 
and local progression of cancer in a previously irradiated 
site could be very difficult. We present the case of pa-
tient eligible for re-irradiation of metastases in thoracic 
spine, which during autopsy turned out to be a necrosis 
after previous palliative hypofractionated radiotherapy.
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A 55-year-old female patient with metastatic ductal 
breast cancer was admitted to the Clinic of Oncology 
and Radiotherapy of the Medical University of Gdańsk 
in October 2013 for re-irradiation of metastases in the 
spine. No major concomitant diseases were revealed. 
In January 2012 right mastectomy was carried out due 
to breast cancer pT2N1M0 with subsequent adjuvant 
hormone therapy. During the course of adjuvant treat-
ment bone metastases were diagnosed. In September 
2012 the patient had palliative radiotherapy with irra-
diation of thoracic part of spinal cord (Th6–Th10; area 
of 6 cm × 10 cm) with dose of 20 Gy divided into four 
fractions (one fraction per day) specified to a depth of 
9 cm from skin, using 2D technique and single photon 
beam with energy 6 MV. During hospital admission for 
re-irradiation the patient was in a moderately severe 
general condition with signs and symptoms of pneumo-
nia. The medical history revealed compassing abdomen 
pain, radiating to lower extremities, which progressed 
during the previous two months, and loss of bladder and 
bowel control of two weeks’ duration. Patient received 
dexamethasone (daily dose of 24 mg). Neurological ex-
amination revealed symmetrical lemniscus disturbances 
of sensation from the level Th6, mainly in proximal parts, 
muscle weakening, and bilateral pyramidal symptoms of 
lower extremities. All those signs and symptoms indi-
cated transverse interruption of the spinal cord on the 
level Th6. Magnetic resonance imaging (MRI) showed 
numerous lytic and sclerotic focuses in vertebrae trunks 
of the thoracic and lumbar part of the spine, with no loss 
of vertebral height. T2 imaging showed increased signal 
of spine from Th2 to Th11, which could correspond to 
post-irradiation changes. Additionally there was visible 
band-like area of contrast spinal cord enhancement on 
the level Th9–10–11 with a length of 54 mm and width of 
8 × 9 mm that showed no abnormal signals in T1 imaging 
before intravenous contrast medium administration and 
was of potential concern due to secondary infiltration. 
In order to distinguish cancer invasion from post-irradi-
ation changes positron emission tomography–computed 
tomography (PET-CT) — was done with administration 
of fluorodeoxyglucose, but due to technical issues it was 
non-diagnostic. 
Concomitant pulmonary invasive aspergillosis was 
diagnosed. Despite targeted antifungal and antibacterial 
treatment, the patient died. The autopsy revealed nu-
merous, partially fungal pulmonary abscesses and necro-
sis of neural tissue in specimens of spinal cord, involving 
central the thoracic part and nearly the whole area of 
spinal cord cross-section. Necrosis was accompanied by 
thickening and vitrification of the walls of arterioles in 
spinal cord. There were numerous metastases in bones, 
ovaries, and bone morrow although there were no cancer 
cells in the spinal cord.
Discussion
Post-irradiation necrosis of spinal cord is an uncom-
mon serious complication of palliative radiotherapy of 
cancer metastases to the spine [7, 8]. As patients with 
advanced breast cancer are continuously living longer 
this issue could have increasing importance [9]. 
Neurological signs and symptoms of post-irradiation 
necrosis of spinal cord may appear months to years after 
radiotherapy [10]. Some authors described short time to 
spinal cord involvement — 3 to 8 months with median 
of 5 months [9]. The intensity of symptoms increases in 
time and, depending on the injury level, involve numb-
ness and hyperesthesia of distal parts of limbs, constric-
tor dysfunctions, and progressing muscle weakening, 
most commonly leading to para- or tetraplegia [11]. 
The damage of endothelial cells and oligoden-
drocytes has a crucial role in the pathophysiology of 
post-irradiation necrosis of the spinal cord [12]. Studies 
conducted on the spinal cords of rats with use of con-
ventional doses of irradiation showed the loss of myelin 
commencing two weeks after radiotherapy cessation and 
progressing during subsequent months [12].
There are many different factors, besides total and 
fractional dose, that impact the risk of post-irradiation 
necrosis of the spinal cord [13, 14]. Total duration of 
irradiation, intervals between fractions, the extent of the 
irradiated area of spinal cord, and individual – mostly 
unpredictable – susceptibility to irradiation are of sig-
nificant importance. Diabetes and vascular diseases as 
well as concomitant chemotherapy additionally may 
increase the risk of post-irradiation injuries. The risk 
of post-irradiation necrosis significantly grows after 
exceeding the biological dose expressed as an equivalent 
dose in 2 Gy fraction (EQD2) amounting to 50 Gy and 
is estimated at 0.2%, 6%, and 50% after administra-
tion of an EQD2 dose of 50 Gy, 60 Gy, and 69 Gy, 
respectively [15]. In the case of re-irradiation the risk 
of post-irradiation necrosis significantly increases and 
depends mainly on the sum biological dose. The time 
since first irradiation has additional importance with re-
spect to repairing processes of post-irradiation damage. 
Those processes go fastest during first eight weeks after 
irradiation; approximately 50% of post-irradiation dam-
age regenerates after six months, but they are observed 
even 1–3 years after radiotherapy [16]. In the presented 
patient the isodose curve capturing spinal cord ac-
counted for approximately 120% of the requested dose. 
Assuming that the a/b ratio for spinal cord amounts to 
2 Gy, the EQD2 dose given to the spinal cord was ap-
proximately 48–49 Gy. 
The main goal of differential diagnosis of post-ir-
radiation necrosis of the spinal cord is the exclusion of 
other reasons for neurological symptoms, particularly 
local progression of cancer, which could be an indica-
tion for re-irradiation. However, magnetic resonance 
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imaging, which is the method of choice, typically re-
veals only unspecific changes, including strong signal 
in T2 imaging, oedema of spinal cord in T1 imaging, 
and annular focuses in spinal cord after contrast me-
dium administration [17]. PET-CT imaging is more 
specific in differentiating post-irradiation myelopathy 
[18]. Contrary to cancer infiltration, which intensively 
uptakes fluorodeoxyglucose, the necrotic changes do not 
show such an uptake of radiotracer. However, a case of 
post-irradiation damage of spinal cord with enhanced 
uptake in PET-CT was described, interpreted as being 
the result of a lack of myelin in neural fibres in the ir-
radiated area [19]. Use of 11C-choline as a radiotracer 
increases the specificity and sensitivity of PET-CT in the 
differentiation of cancer relapse and post-irradiation in 
the central nervous system [20]. 
Therapeutic options in post-irradiation necrosis of 
spinal cord are limited. In some cases objective improve-
ment could be achieved after administration of steroids, 
hyperbaric oxygen, alpha-tocopherol, deferoxamine, 
warfarin, and heparin as well as bevacizumab [21]. 
In the presented article we described the difficulties 
in diagnosis of post-irradiation necrosis of the spinal 
cord. In the presented case this severe complication oc-
curred after hypofractionated radiotherapy with a dose 
of 20 Gy given in four fractions, which corresponded to 
a biological dose of relative safety. The reasons for the 
described fatal myelopathy remain unknown; one pos-
sibility is specific individual sensitivity of the patient to 
ionising radiation. 
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